uMedical
Medicines
Substances
Companies
Statistics
Menu
All medicines
Canakinumab Novartis
Application withdrawn
Human
Details
EMA number
EMEA/H/C/004754
ATC code
L04AC08
Authorisation
-
Revision
-
EMA page
Therapeutic indication
Prevention of major cardiovascular events
MeSH:
Acute Coronary Syndrome;Myocardial Infarction;Stroke
Group:
Immunosuppressants
Active substances
canakinumab
Marketing Authorisation Holder
Novartis Europharm Limited
MAH
Canakinumab Novartis | uMedical